re: hmmm. intelligent investor This report is not logically coherent. At the core of all stock prices is the Net Present Value [NPV] of future cash flows.
With stocks with forecastable cash flows eg banks analysts can agree within a reasonable range.
With biotechs you have to incorporate risk and market penetration to get revenue and then add timing issues.
However, the news that QF-Gold was immune to BCG was much more important than a delay to revenue from QF-1.
The risk is very low for QF-Gold so CST has a much higher potential revenue with a moderate delay of say 1-2 years - this is a better NPV outcome than the QF-1 model. If only QF-1 was available and its revenue was delayed then the present valuation should be lowered.
- Forums
- ASX - By Stock
- CST
- hmmm.
hmmm., page-17
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CST (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.90M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6699 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 331144 | 3 |
Last trade - 10.27am 04/12/2024 (20 minute delay) ? |
Featured News
CST (ASX) Chart |
Day chart unavailable